Sep 19, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
English
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
English
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
Swedish
Corporate Action
Other
Aug 30, 2023, 14:00
News
IR
Swedish
Corporate Action
Other
Aug 29, 2023, 09:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Aug 22, 2023, 09:00
News
IR
Swedish
Corporate Action
Other
mfn-cus-disclaimer
Aug 22, 2023, 09:00
News
IR
English
Corporate Action
Other
mfn-cus-disclaimer
Aug 17, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Aug 17, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Aug 16, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Aug 16, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Aug 09, 2023, 18:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Jul 13, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Jul 13, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Jun 19, 2023, 08:15
News
IR
English
Corporate Action
Other
Jun 19, 2023, 08:15
News
IR
Swedish
Corporate Action
Other
Jun 09, 2023, 08:30
News
IR
English
Corporate Action
Other
Jun 09, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se